Article Text

Download PDFPDF

Does smoking cessation with varenicline worsen vascular endothelial function?
  1. Akira Umeda1,
  2. Toru Kato2,
  3. Tateki Yamane1,
  4. Heiichi Yano1,
  5. Tamio Ieiri1,
  6. Kazuya Miyagawa3,
  7. Hiroshi Takeda3,
  8. Yasumasa Okada4
  1. 1Department of Internal Medicine, International University of Health and Welfare Shioya Hospital, Tochigi, Japan
  2. 2Department of Clinical Research, National Hospital Organization Tochigi Medical Center, Tochigi, Japan
  3. 3Department of Pharmacology, School of Pharmacy, International University of Health and Welfare, Tochigi, Japan
  4. 4Department of Internal Medicine, National Hospital Organization Murayama Medical Center, Tokyo, Japan
  1. Correspondence to Dr Akira Umeda; aumeda{at}


Objectives A meta-analysis suggested that the use of varenicline, which is a partial agonist of nicotinic acetylcholine receptors and is effective in smoking cessation, increases the risk of cardiovascular events within 52 weeks of starting treatment. Defining these events as occurring during drug treatment (usually for 12 weeks) or within 30 days of discontinuation, another meta-analysis showed that the risk was statistically insignificant. In the present study, we aimed to clarify the effect of varenicline-assisted smoking cessation on vascular endothelial function assessed by flow-mediated vasodilation (FMD).

Design Before–after and time-series.

Setting Tochigi Prefecture, Japan.

Participants Data of 85 participants who visited nicotine-dependent outpatient services were reviewed. FMD was repeatedly measured in 33 of the 85 participants. Inclusion criteria: 20 years and older, Brinkman index ≥200, Tobacco Dependence Screener ≥5 and stated motivation to quit smoking.

Interventions Each participant was treated with varenicline titrated up to 1.0 mg twice daily (for 12 weeks in total).

Primary and secondary outcome measures Participants were evaluated by FMD prior to, and 3 months after, complete smoking cessation. Follow-up FMD measurements were carried out every 3 months if possible. Changes in FMD during varenicline use were also evaluated.

Results FMD was significantly increased from 4.0±1.8% to 5.5±2.2% (p<0.01, n=22) 3 months after complete cessation. Although the timecourse of FMD in most of the cases showed an increase with fluctuations, there was an exceptional case where FMD decreased over the 9 months following complete cessation. Although statistically insignificant, FMD also increased during varenicline use (from 3.7±2.7% to 4.3±2.8%, n=11).

Conclusions Our observations suggest that in ceasing smokers, varenicline and smoking cessation do not lead to a worsening of the vascular endothelial function.

Trial registration FK-79 (International University of Health and Welfare).

  • varenicline
  • smoking cessation
  • endothelial function
  • FMD

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: and

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.